The first day of the LSI Asia’s Emerging Medtech conference in Singapore has been superb – and particularly pleased with the response from my presentation on our Callavid® vaginal drug delivery platform.  Driven by growing regional concerns over declining fertility and birth rates across Asia, our initial focus on supporting IVF and miscarriage prevention has struck a chord.  Combined with the general momentum and interest in everything women’s health – there’s been a real buzz and am delighted to be making meaningful connections as we look for partners and collaborators to execute an Asian strategy!  🇸🇬 🇯🇵 🇰🇷 🇨🇳 🇻🇳